GLP1R and cardiac hypertrophy: The cardiovascular impacts linked to GLP-1 agonists improve the prognosis of COVID-19 diabetic patients [45,46] since they effectively reduce ventricular hypertrophy, optimizing cardiac functions and hypertension values [44].